Calidi Biotherapeutics reports Q3 net loss of $5.2M; cash at $10.4M after $6.9M offering

Calidi Biotherapeutics, Inc.

2025-Q3 EPS reported -$6.40

Net loss $5.2M in Q3 2025; net loss attributable to shareholders $10.8M due to non-cash deemed dividend on warrants.
Basic/diluted EPS loss $2.21 vs $7.75 prior year; cash $10.4M plus $0.2M restricted at Sep 30.
Gross proceeds of $6.9M from underwritten public offering; total 2025 gross proceeds $23.0M.
Presented CLD-401 preclinical data at SITC; new Scientific Advisory Board with four experts established.
RedTail platform expands targeting capabilities and payloads; CLD-401 advancing to IND-enabling studies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.